Rocrock Bio develops CAR-M therapies utilizing genetically engineered macrophages to target and treat solid tumors, addressing the challenges of traditional cancer treatments. Their technology enhances macrophage cultivation and gene transfer, providing a potential solution for improved tumor management and patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors pose significant challenges for traditional cancer treatments due to their complex microenvironment and resistance to conventional therapies. Current approaches often fail to effectively penetrate and eliminate tumor cells, leading to recurrence and limited patient survival. Effective targeting and modulation of the tumor microenvironment remain critical unmet needs in oncology.
Solution
Rocrock Bio develops CAR-M (Chimeric Antigen Receptor Macrophage) therapies, an innovative approach that leverages genetically engineered macrophages to target and treat solid tumors. Their technology enhances macrophage cultivation and gene transfer, enabling the creation of CAR-M cells that can specifically recognize and infiltrate tumor tissue. These engineered macrophages are designed to overcome the immunosuppressive barriers within the tumor microenvironment, promoting direct tumor cell killing and stimulating a broader anti-tumor immune response. By harnessing the innate ability of macrophages to infiltrate and remodel tissues, Rocrock Bio aims to provide a more effective and targeted treatment option for patients with solid tumors. The company's approach seeks to improve tumor management and ultimately enhance patient outcomes.
Target Audience
The primary target audience includes patients with solid tumors who have limited treatment options, as well as oncologists and clinical researchers seeking innovative approaches to cancer immunotherapy.
Features
- CAR-M cell therapy platform utilizing genetically engineered macrophages
- Macrophage-specific CAR design technology platform
- Optimized macrophage cultivation techniques for enhanced cell expansion and viability
- Rapid monocyte infection and culture technology platform
- Macrophage-specific virus modification technology platform
- Pipeline of CAR-M therapies targeting various solid tumors, including RR-M01 for liver cancer
- Technology designed to overcome challenges in macrophage cultivation, gene transfer, and tumor infiltration